Roche Holdings AG Basel (OTCMKTS:RHHBY) Downgraded by Liberum Capital to “Hold”

Liberum Capital lowered shares of Roche Holdings AG Basel (OTCMKTS:RHHBY) from a buy rating to a hold rating in a report released on Thursday, The Fly reports.

Separately, Deutsche Bank raised Roche Holdings AG Basel from a hold rating to a buy rating in a report on Thursday. Seven equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The stock currently has an average rating of Hold and an average target price of $34.50.

OTCMKTS RHHBY opened at $35.60 on Thursday. The company has a market capitalization of $243.27 billion, a PE ratio of 15.34, a P/E/G ratio of 2.57 and a beta of 0.46. Roche Holdings AG Basel has a 12 month low of $26.96 and a 12 month high of $35.90.

Institutional investors have recently made changes to their positions in the business. Advisors Asset Management Inc. acquired a new stake in Roche Holdings AG Basel during the 1st quarter valued at $144,000. Beck Mack & Oliver LLC acquired a new stake in Roche Holdings AG Basel during the 1st quarter valued at $203,000. South Texas Money Management Ltd. acquired a new stake in Roche Holdings AG Basel during the 1st quarter valued at $215,000. MAI Capital Management acquired a new stake in Roche Holdings AG Basel during the 1st quarter valued at $220,000. Finally, Dearborn Partners LLC lifted its holdings in Roche Holdings AG Basel by 11.9% during the 1st quarter. Dearborn Partners LLC now owns 9,339 shares of the company’s stock valued at $321,000 after purchasing an additional 992 shares during the last quarter. 0.30% of the stock is owned by institutional investors and hedge funds.

Roche Holdings AG Basel Company Profile

Roche Holding AG engages in the diagnostics and prescription pharmaceuticals businesses in Switzerland, Germany, and internationally. It offers pharmaceutical products for treating anaemia, anticoagulation therapy, bone, cardiovascular, central nervous system, chlamydia, coagulation, dermatology, diabetes, gonorrhea, gout, hemostasis disorders, hepatitis B and C, HIV/AIDS, HPV, inflammatory and autoimmune, intensive care medicine, kidney and urogenital tract, leukemia, lipid and liver disorders, lymphoma, metabolic disorders, obesity, occult blood testing, ophthalmology, osteoporosis, pancreatitis, respiratory disorders, rheumatoid arthritis, sepsis, sexually transmitted infections, skin cancer, transplantation, tuberculosis, urinary tract infections, and West Nile virus and infectious diseases.

Read More: How does a security become overbought?

The Fly

Analyst Recommendations for Roche Holdings AG Basel (OTCMKTS:RHHBY)

Receive News & Ratings for Roche Holdings AG Basel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche Holdings AG Basel and related companies with MarketBeat.com's FREE daily email newsletter.